IFPMA

STATEMENT

Pharmaceutical innovation key to delivering G7 leaders' growth agenda

18 JUNE 2026, GENEVA – The global innovative pharmaceutical industry welcomes the G7 leaders' commitment to strengthening international cooperation and advancing a balanced and durable growth agenda. IFPMA supports the direction G7 leaders have set and reiterates that a strong life sciences sector is critical to support these shared objectives.

Pharmaceutical innovation at the core of G7 priorities

G7 leaders have adopted their joint commitment to achieve a stronger and more resilient global economy, and the innovative pharmaceutical industry stands out as a central contributor to that vision. The industry is the world's most R&D-intensive sector, supports millions of high-value jobs across G7 economies, and drives cutting-edge innovation that lifts productivity across the broader economy. As leaders look to achieve durable growth and correct imbalances, the pharmaceutical industry will be a critical partner.

The G7's first declaration on cancer marks an important step forward. With nearly 5,000 cancer medicines in the pipeline, the potential to revolutionize care is significant, but sustained progress will depend on policies that value and reward innovation across the continuum of care. Key to unlocking future scientific progress is prioritizing innovative medicines and vaccines as strategic investments that drive both improved health outcomes and long-term economic returns.

The same imperative applies to global health threats. The Bundibugyo Ebola outbreak underscores that prevention, preparedness, and response depend on sustained innovation. We welcome leaders' recognition of the private sector's important role to accelerate the tools needed to contain it.

As leaders have expressed, delivering on these commitments will depend on strong, mutually beneficial international partnerships and a supportive investment and policy environment that enables key sectors, such as pharmaceuticals, to drive growth.

Charting the path forward

The innovative pharmaceutical industry continues to remain a strategic partner to G7 countries in delivering on these priorities. Pharmaceutical innovation is the engine that drives all these ambitions toward shared prosperity and better outcomes for patients, societies, and economies.

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org
ifpma.org

@IFPMA
/IFPMA

Building on the commitments outlined at the G7 Leaders' Summit, the industry reiterates three key imperatives for G7 leaders:

- **Invest in innovative medicines and vaccines** for long-term economic, societal, and health returns.
- **Prioritize the innovative pharmaceutical industry as a strategic sector**, central to growth, competitiveness, and resilience.
- **Strengthen the G7's leadership in pharmaceutical innovation**, with a forward-looking strategy to sustain its competitive advantage.

The innovative pharmaceutical industry stands ready to continue to work alongside G7 governments to translate the direction set in Evian into sustainable outcomes for all.

Note to the editors:

IFPMA and Leem Press Release Pharmaceutical industry calls on G7 to invest in innovation to drive competitiveness, resilience, and growth (11 June 2026)

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org
ifpma.org

@IFPMA
/IFPMA